EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intranasal Administration of Extracellular Vesicles Derived from Adipose Mesenchymal Stem Cells Has Therapeutic Effect in Experimental Autoimmune Encephalomyelitis

Barbara Rossi iD, Federica Virla iD, Gabriele Angelini, Ilaria Scambi iD, Alessandro Bani, Giulia Marostica, Mauro Caprioli, Daniela Anni, Roberto Furlan iD, Pasquina Marzola iD, Raffaella Mariotti, Gabriela Constantin iD und 2 weitere

Cells · 30.07.2025 · 14 (15) · 1172

DOI: 10.3390/cells14151172 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 30.07.2025. Verfasst von Barbara Rossi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Pathology, Department of Medicine, University of Verona, 37134 Verona, Italy. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, Extracellular Vesicles, Mesenchymal Stem Cells, Adipose Tissue. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione Italiana Sclerosi Multipla (FIMS), National Recovery and Resilience Plan (NRRP), European Union—NextGenerationEU—CUP.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adipose stem cells (ASCs) are a subset of mesenchymal stem cells with validated immunomodulatory and regenerative capabilities that make them attractive tools for treating neurodegenerative disorders, such as multiple sclerosis (MS). Several studies conducted on experimental autoimmune encephalomyelitis (EAE), the animal model of MS, have clearly shown a therapeutic effect of ASCs. However, controversial data on their efficacy were obtained from I- and II-phase clinical trials in MS patients, highlighting standardization issues and limited data on long-term safety. In this context, ASC-derived extracellular vesicles from (ASC-EVs) represent a safer, more reproducible alternative for EAE and MS treatment. Moreover, their physical characteristics lend themselves to a non-invasive, efficient, and easy handling of intranasal delivery. Using an in vitro setting, we first verified ASC-EVs’ ability to cross the human nasal epithelium under an inflammatory milieu. Magnetic resonance corroborated these data in vivo in intranasally treated MOG35-55-induced EAE mice, showing a preferential accumulation of ASC-EVs in brain-inflamed lesions compared to a stochastic distribution in healthy control mice. Moreover, intranasal treatment of ASC-EVs at the EAE onset led to a long-term therapeutic effect using two different experimental protocols. A marked reduction in T cell infiltration, demyelination, axonal damage, and cytokine production were correlated to EAE amelioration in ASC-EV-treated mice compared to control mice, highlighting the immunomodulatory and neuroprotective roles exerted by ASC-EVs during EAE progression. Overall, our study paves the way for promising clinical applications of self-administered ASC-EV intranasal treatment in CNS disorders, including MS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Encephalomyelitis, Autoimmune, ExperimentalExtracellular VesiclesMesenchymal Stem CellsAdipose TissueMesenchymal Stem Cell TransplantationAnimalsAdministration, IntranasalHumansMiceFemaleMice, Inbred C57BL

Stichwörter der Autor:innen

EAEadipose mesenchymal stem cellsextracellular vesiclesmultiple sclerosisstem cells

Autor:innen und Institutionen

  • Division of General Pathology, Department of Medicine, University of Verona, 37134 Verona, Italy.
  • Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.
  • Clinical Neuroimmunology Unit, Institute of Experimental Neurology, San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Department of Engineering for Innovation Medicine, University of Verona, 37134 Verona, Italy.
  • Neurology Unit, Azienda Ospedaliera Universitaria Integrata Verona, 37126 Verona, Italy.

ORCID-Profile: Barbara Rossi, Federica Virla, Ilaria Scambi, Roberto Furlan, Pasquina Marzola, Gabriela Constantin, Ermanna Turano

Förderung

  • Fondazione Italiana Sclerosi Multipla (FIMS)
  • National Recovery and Resilience Plan (NRRP)
  • European Union—NextGenerationEU—CUP

Zitieren

APA

Rossi, B., Virla, F., Angelini, G., Scambi, I., Bani, A., Marostica, G., Caprioli, M., Anni, D., Furlan, R., Marzola, P., Mariotti, R., Constantin, G., Bonetti, B., & Turano, E. (2025). Intranasal Administration of Extracellular Vesicles Derived from Adipose Mesenchymal Stem Cells Has Therapeutic Effect in Experimental Autoimmune Encephalomyelitis. Cells, 14(15), 1172. https://doi.org/10.3390/cells14151172

Vancouver

Rossi B, Virla F, Angelini G, Scambi I, Bani A, Marostica G, et al. Intranasal Administration of Extracellular Vesicles Derived from Adipose Mesenchymal Stem Cells Has Therapeutic Effect in Experimental Autoimmune Encephalomyelitis. Cells. 2025;14(15):1172. doi:10.3390/cells14151172

BibTeX
@article{Rossi2025,
  author = {Rossi, Barbara and Virla, Federica and Angelini, Gabriele and Scambi, Ilaria and Bani, Alessandro and Marostica, Giulia and Caprioli, Mauro and Anni, Daniela and Furlan, Roberto and Marzola, Pasquina and Mariotti, Raffaella and Constantin, Gabriela and Bonetti, Bruno and Turano, Ermanna},
  title = {Intranasal Administration of Extracellular Vesicles Derived from Adipose Mesenchymal Stem Cells Has Therapeutic Effect in Experimental Autoimmune Encephalomyelitis},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {15},
  pages = {1172},
  doi = {10.3390/cells14151172}
}
Kostenlos starten →